Figure 4

Kaplan-Meier plot of percent survival over time in advanced-stage IGROV-1 ovarian tumor-bearing mice. (A) Mice selected for the presence of evident and established ascites from a large group of mice injected i.p. 11 days before with IGROV-1 cells (mean body weight ± SEM 27.89 ± 0.84 g vs 23.00 ± 1.08 g before tumor cell injection) were treated with saline, Cisplatin (3 mg/kg, once per week), CpG-ODN (20 μg/mouse, 5 days/week for 4 weeks) plus Cetuximab (1 mg/mouse at 3- to 4-day intervals), CpG-ODN plus Cisplatin, Cetuximab plus Cisplatin, and CpG-ODN plus Cetuximab and Cisplatin. (B) Mice selected for more advanced-stage disease (mean body weight ± SEM 31.4 ± 0.9 g vs 24.89 ± 0.68 g before tumor cell injection) were treated with saline or CpG-ODN plus Cetuximab and Cisplatin. N = number mice/group.